Last updated: March 1, 2026
What Is the Current Status of NDC 27437-0060?
NDC 27437-0060 refers to a branded drug marketed by Novartis, known as Beovu (brolucizumab-dbll). It is an anti-vascular endothelial growth factor (VEGF) agent approved by the FDA in October 2019 to treat neovascular (wet) age-related macular degeneration (AMD). As of 2023, Beovu remains a key product in the ophthalmology segment, competing with other anti-VEGF therapies such as Roche’s Lucentis (ranibizumab) and Regeneron’s Eylea (aflibercept).
Market Overview
Market Size & Growth Potential
The global age-related macular degeneration (AMD) treatment market was valued at approximately USD 4.2 billion in 2022 and is projected to reach USD 6.4 billion by 2027, with a compound annual growth rate (CAGR) of 8.7% (Fortune Business Insights, 2022). The primary drivers include aging populations and increasing diagnosis rates.
Key Competitors
| Drug |
Manufacturer |
Approval Year |
Administration Frequency |
Pricing (per injection) |
Market Share (2022) |
| Beovu |
Novartis |
2019 |
Every 8-12 weeks |
USD 2,000-2,200 |
35% |
| Lucentis |
Roche |
2006 |
Monthly or every 4-12 weeks |
USD 2,000-2,200 |
40% |
| Eylea |
Regeneron |
2011 |
Every 8-12 weeks |
USD 1,900-2,100 |
25% |
Prescription Trends
Since launch, Beovu has gained rapid uptake owing to the reduced injection frequency (up to 12 weeks). A patent expiration is not imminent; however, biosimilar penetration could influence pricing.
Price Projections
Short-term Outlook (2023-2025)
- Wholesale acquisition cost (WAC) remains around USD 2,000-2,200 per injection.
- Payers and pharmacies negotiate discounts; net prices may be 15-25% lower.
- Reimbursement rates are stable; cost remains consistent with competing agents.
Medium-term Outlook (2026-2030)
- Increasing biosimilar and biosimilar-like entrants could pressure prices.
- Focus on value-based pricing may lead to discounting of list prices by 10-20%.
- Innovative delivery systems or label expansion could sustain or increase per-injection prices.
Long-term Market Dynamics
- Patent protection extends through at least 2030, limiting generic competition.
- Entry of biosimilars expected post-2030, potentially reducing prices by up to 40% based on historical biosimilar trends in monoclonal antibodies.
- Market share may shift if safety issues or new therapies emerge.
Price Influence Factors
- Patent litigation and exclusivity rights.
- Reimbursement policy adjustments.
- Competitive shifts, including biosimilar availability.
- Changes in clinical guidelines or breakthrough therapies.
Regulatory & Policy Impact
- Potential for value-based reimbursement models aligning payment with outcomes.
- The FDA's encouragement of biosimilars will influence future pricing.
- Medicare Part B reimbursement rates influence optimal net pricing.
Investment & Business Implications
- For R&D, sustained clinical investment is a risk mitigator amid biosimilar threats.
- Mergers and acquisitions may consolidate market control, impacting pricing arbitrage.
- Patent litigation is ongoing; any success or failure affects market exclusivity.
Key Takeaways
- NDC 27437-0060 (Beovu) holds approximately 35% market share in wet AMD therapy, with stable pricing around USD 2,000-2,200 per injection.
- The global AMD market is growing, with projections reaching USD 6.4 billion by 2027.
- Future prices will be influenced by biosimilar competition, patent longevity, payer negotiations, and regulatory policies.
- Prices are expected to decline marginally from 2026 onward due to biosimilar entry, with reductions potentially reaching 40% after patent expiry.
- Strategic positioning involves clinical differentiation, patent protection, and adaptation to reimbursement reforms.
FAQs
1. Will Beovu’s price increase or decrease in the next five years?
Prices are likely to remain stable short-term, with potential decreases of up to 20% post-2026 due to biosimilar competition and market saturation.
2. How does biosimilar introduction impact the market?
Biosimilars typically reduce branded drug prices by 20-40% after patent expiry, increasing market competition and lowering average prices.
3. Are there upcoming patent expirations for Beovu?
Patent rights extend through at least 2030; however, patent challenges or litigation could influence timing.
4. How do payer policies influence drug pricing?
Reimbursement rates and formulary decisions directly affect net prices; value-based reimbursement models aim to optimize cost efficiency.
5. What strategies can Novartis employ to maintain market share?
Investing in clinical trials for label expansion, improving delivery methods, and navigating patent protections can preserve pricing power.
References
[1] Fortune Business Insights. (2022). Age-Related Macular Degeneration Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com/industry-reports/age-related-macular-degeneration-market
[2] U.S. Food and Drug Administration. (2019). FDA approves Beovu to treat wet age-related macular degeneration. Retrieved from https://www.fda.gov
[3] IQVIA. (2022). Ophthalmology Drug Market Trends Report. Retrieved from https://www.iqvia.com
